Sponsor hub
Abramson Cancer Center at Penn Medicine clinical trial failures
Review 42 stopped clinical trials from Abramson Cancer Center at Penn Medicine, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 2 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 23
- OTHER/UNKNOWN
- 17
- EFFICACY/FUTILITY
- 2
Notable sponsors
- Abramson Cancer Center at Penn Medicine
- 42
Related phases
- Phase I
- 22
- Phase II
- 15
- Early Phase I
- 4
- Unknown
- 1
Crawlable stopped-trial records
Open ExploreShowing up to 42 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I ALL trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Hepatocellular Carcinoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280) studies. This decision was made based on an internal review and reprioritization of the existing pipeline.
Early Phase I Pancreatic Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: EFFICACY/FUTILITY.
Early analysis of images after 6 patients showed no activity of the radiotracer in this patient population.
Phase I Colorectal Neoplasms Malignant trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
failure to accrue
Phase I Renal Cell Carcinoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
failure to accrue
Early Phase I Pancreatic Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
The accrual goal could not be met and the drug manufacturer pulled support
Phase II Hodgkin Lymphoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Covid-19
Phase II Pancreatic Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Loss of funding
Phase I Melanoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
Difficulty enrolling subjects
Phase II Hepatocellular Carcinoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
Safety letter from sponsor
Phase I Anal Dysplasia trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Covid-19
Phase II Mucinous Adenocarcinoma of the Colon trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Terminated due to slow enrollment and lack of efficacy
Phase I Metastatic sRCC trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
The study was terminated due to protracted accrual and limited patient engagement in the setting of rapidly changing treatment paradigms for advanced RCC with sarcomatoid features and/or intermediate/poor risk clinical features.
Phase I Ovarian Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Due to sponsor request
Phase I Pancreatic Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients and it is not feasible to subtype patients in the short time frame before surgery
Phase II Head and Neck Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
PI left institution
Phase I Ovarian Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: EFFICACY/FUTILITY.
Did not meet criteria laid out in Phase 1 to continue to Phase 2
Phase I Acute Myelogenous Leukemia (AML) trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Non Small Cell Lung Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Insufficient accrual
Phase I Acute Myelogenous Leukemia trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Lymphoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
poor accrual
Unknown Cervical Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Poor accrual/enrollments
Phase II Renal Cell Carcinoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
In November 2012, this study was permanently closed to new accrual at the request of the drug manufacturer (BMS), who decided not to pursue additional research activity in this patient population.
Phase I Pancreas Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Lack of Funding
Phase II Acute Myeloid Leukemia trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
Study terminated. Eisai's Targretin acquired by another pharmaceutical company.
Phase II Lung Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Poor accrual and change in standards of care
Phase II Colorectal Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Due to Poor accrual
Phase I Breast Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
due to business decision regarding the study drug.
Phase I Primary Ovarian Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Ovarian Carcinoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Hepatocellular Carcinoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Lack of enrollment
Phase II Rectal Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
new studies were finding that Erbitux was not beneficial
Early Phase I GI Patients on Oxaliplatin Containing Regimen trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
final study report has been completed and submitted
Phase II Cervical Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Recurrent Glioblastoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Lack of enrollment
Early Phase I Multiple Myeloma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
PI decided to close study due to slow accrual.
Phase II Pancreatic Ductal Adenocarcinoma trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
Halozyme halted development of PEGPH20 following Phase 3 failure.
Phase I Brain and Central Nervous System Tumors trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Insufficient accrual
Phase I Urothelial Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OPERATIONAL.
Insufficient accrual
Phase I Ovarian, Fallopian Tube and Peritoneal Cancer trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Rectal Cancer Patients trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II B-cell Acute Lymphoblastic Leukemia trial by Abramson Cancer Center at Penn Medicine. Stop reason: OTHER/UNKNOWN.
Did not enroll